| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2021: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
The diversity-enhanced extracts were utilized as a basic technology to create a group of compounds with diversity beyond that of natural compounds by directly reacting chemical structures that are not incorporated in biosynthesis with extracts from natural resources. Using medicinal plants containing characteristic components as raw materials, we obtained indole alkaloid-type and terpenoid alkaloid-type compounds using non-natural amines, as well as biaryl and biaryl ether/amine-type compounds commonly found in pharmaceutical structures. As a result of extensive bioactivity screening of these compounds, we found bioactive substances that inhibit the expression of immune checkpoint molecules and inhibit osteoclastic differentiation.
|
